Guess we all have different investment plans & strategies as the PAA story plays out over the next 18 months - 2 years.
Important thing is to plan !
For me, it goes something like this ( until the plan changes of course ! ).
1. News on MPL MoA and possible efficacy against other neurodegenerative conditions, plus Healey first recruitment ( and all the preceding news to this milestone ) should see the company approach a $500M MC, perhaps an initial sign-on deal from a mid-size / big Phrama. So, around $1.00 SP. I'll be taking around 20% off the table at this stage - enough for free carry and to invest in some other life pursuits.
2. The remainder - while the science remains compelling, I'd like to see it through to Healey results come in. If they are as positive as very early indications suggest - well then a $2.5B - $5.0B MC may well be representative of true value.
In the meantime, SP machinations remain background noise.
ALL IMO.
Definitely not financial advice
- Forums
- ASX - By Stock
- Pharmaust - Media & News
Guess we all have different investment plans & strategies as the...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.5¢ |
Change
0.005(2.63%) |
Mkt cap ! $94.89M |
Open | High | Low | Value | Volume |
19.0¢ | 19.5¢ | 19.0¢ | $58.40K | 305.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 115000 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.5¢ | 86074 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.190 |
8 | 156232 | 0.185 |
10 | 635662 | 0.180 |
10 | 482365 | 0.175 |
8 | 151233 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.195 | 86074 | 3 |
0.200 | 256824 | 3 |
0.205 | 113150 | 5 |
0.210 | 333355 | 8 |
0.215 | 266995 | 7 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
PAA (ASX) Chart |